Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 2022

被引：1
|
作者：
Benjamin, David J. [1 ,3 ]
Kalebasty, Arash Rezazadeh [2 ]
机构：
[1] Hoag Family Canc Inst, Newport Beach, CA USA
[2] Univ Calif Irvine, Med Ctr, Dept Med, Div Hematol Oncol, Orange, CA USA
[3] Hoag Family Canc Inst, 1 Hoag Dr,Bldg 41, Newport Beach, CA 92663 USA
来源：
CLINICAL MEDICINE INSIGHTS-ONCOLOGY | 2024年 / 18卷
关键词：
D O I：
10.1177/11795549241227413
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] New drug development in metastatic prostate cancer
    Armstrong, Andrew J.
    George, Daniel J.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2008, 26 (04) : 430 - 437
  • [22] The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004
    Lichtenberg, Frank R.
    [J]. ECONOMICS OF INNOVATION AND NEW TECHNOLOGY, 2009, 18 (05) : 407 - 428
  • [23] Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer A Secondary Analysis of a Randomized Clinical Trial
    Ali, Adnan
    Hoyle, Alex
    Haran, Aine M.
    Brawley, Christopher D.
    Cook, Adrian
    Amos, Claire
    Calvert, Joanna
    Douis, Hassan
    Mason, Malcolm D.
    Dearnaley, David
    Attard, Gerhardt
    Gillessen, Silke
    Parmar, Mahesh K. B.
    Parker, Christopher C.
    Sydes, Matthew R.
    James, Nicholas D.
    Clarke, Noel W.
    [J]. JAMA ONCOLOGY, 2021, 7 (04) : 555 - 563
  • [24] Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
    de Bono, Johann S.
    Scher, Howard I.
    Montgomery, R. Bruce
    Parker, Christopher
    Miller, M. Craig
    Tissing, Henk
    Doyle, Gerald V.
    Terstappen, Leon W. W. M.
    Pienta, Kenneth J.
    Raghavan, Derek
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (19) : 6302 - 6309
  • [25] Estimating survival benefit in castrate metastatic prostate cancer: Decision making in proceeding to a definitive phase III trial
    Verbel, DA
    Kelly, WK
    Smaletz, O
    Regan, K
    Curley, T
    Heller, G
    Scher, HI
    [J]. UROLOGY, 2003, 61 (01) : 142 - 144
  • [26] Survival Benefit of Gastric Resection in the Setting of Metastatic Gastric Cancer
    Nguyen, T.
    Vuong, B.
    Wang, M.
    Fischer, T.
    Goldfarb, M.
    Bilchik, A.
    Foshag, L.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S210 - S210
  • [27] Measures of survival benefit in cancer drug development and their limitations
    Etzioni, Ruth
    Gulati, Roman
    Lin, Daniel W.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (03) : 122 - 127
  • [28] Survival in Patients With De Novo Metastatic Prostate Cancer
    Schoen, Martin W.
    Montgomery, R. Bruce
    Owens, Lukas
    Khan, Saira
    Sanfilippo, Kristen M.
    Etzioni, Ruth B.
    [J]. JAMA NETWORK OPEN, 2024, 7 (03)
  • [29] Re: Darolutamide and Survival in Metastatic, Hormonesensitive Prostate Cancer
    Vilaseca, Antoni
    Ribal, Maria J.
    [J]. EUROPEAN UROLOGY, 2022, 82 (05) : 573 - 573
  • [30] Re: Abiraterone and Increased Survival in Metastatic Prostate Cancer
    Cheetham, Philippa J.
    Petrylak, Daniel P.
    [J]. EUROPEAN UROLOGY, 2012, 61 (04) : 850 - 850
12345